<a href="https://laohu8.com/S/WGRX">Wellgistics Health Inc.</a> Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024
Wellgistics Health Inc. (NASDAQ:WGRX) reported financial results for the second fiscal quarter ending June 30, 2025. The company's revenue on a pro forma basis for the first half of 2025 stood at $18.65 million, compared to $18.25 million in the first half of 2024, reflecting a slight increase. Since its initial public offering in February 2025, Wellgistics Health has consolidated its operations, streamlined staffing, and upgraded its ERP system to support growth. The company is also expanding its direct-to-patient programs, leveraging a network of over 6,500 independent pharmacies and 200 manufacturers to enhance its reach in therapeutic areas such as diabetes, weight loss, chronic pain, sleep disorders, and men's and women's health. The CEO emphasized the company's focus on accelerating growth through strategic funding and expanding access via its direct-to-patient delivery models.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063183) on August 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.